FibroGen's Pamrevlumab Therapy Fails to Show Efficacy in Late-Stage Study.

FibroGen's lead candidate, pamrevlumab, has failed a Phase III study in Duchenne muscular dystrophy, causing shares to fall 9% in pre-market trading. The drug was being developed alongside anemia drug roxadustat, which has also faced multiple setbacks in clinical and regulatory trials.